Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
AdLaunch is an online video maker tool aimed at social media advertising creation. Using its patented AI-powered video generation technology, it enables businesses to create multiple high-quality videos, realtime previews and edit videos in the browser itself. This helps companies undertake online video advertising almost instantaneously within their respective budgets. AdLaunch has 11,000 users in over 130 countries worldwide. It has made 1.4 million pre-licensed HD videos and high-quality photos. The company aims to become synonymous with creating data-driven video ads and video campaigns. AdLaunch was awarded the 'Third Prize' at the Slush 100 pitch competition out of 2650 companies. it also secured three government R&D grants totaling £219,000 from the Business Finland - the Finnish Innovation Agency. AdLaunch is partnering with AppSumo which has a user base of 730,000 registered newsletter readers. With the proceeds, the company will develop its video generator and invest £8000 per month on Google, Facebook, and YouTube advertising to accelerate its customer acquisition.
days to go:
Expired
investment:
£85,278
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
Studio Pictures Limited is a UK based production company that specialises in the development of high-quality British film and TV projects. The company's interest predominantly lies within the British film and television industry that can be created within budget ranging from £1 million - £15 million. The company has established relationships with studio houses such as Warner Bros., Sony Pictures and Lionsgate and aims to build upon projects that can be made into a franchise. Their production, A Steet Cat Named Bob, went on to be distributed by Sony Pictures in the UK and had a Royal Premiere in London. Studio Pictures Limited will consider putting up to a maximum of 20% of the budget for each project as equity, on a case by case basis, subject to company reserves. With the proceeds, the company will grow and scale the business. It will become a tenant at Twickenham Studios in West London and look to profitable emerging markets, i.e. streaming, animation and interactive movies to become one of the leading UK production companies.
days to go:
Expired
investment:
Withheld
Perspective Pictures is a creative, digital-first video production company based in North London. The company asserts that existing video production companies produce good TV advertisements and long-form pieces for brands but fail to find an engaged online audience. PP asserts that its team of employees with an average age of 25, and in-house production crew and creatives allow it to produce a variety of video ads from a short snappy, subtitled Facebook ad to a long-form 22 minute YouTube series drawing in the target audience. The company sold over £200,000 worth of video content in the first 60 days of 2020. It has featured in news publications like The Evening Standard, Forbes, BA BusinessLife, Moneyweek, and Shortlist. PP will use the investment to make £2 million worth of video content per year, invest in team training and education to ensure that it can offer the best service/product to its clients, and help manage cash flow and unexpected situations.
days to go:
Expired
investment:
£108,046
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
Feed is a platform that automates digital advertising for musicians and creators by enabling them to grow an audience and build their businesses. The creator needs to connect their social media accounts to the Feed portal and set a budget. The portal will then create ads that reach new people and convert engaged audiences into loyal fans over time. The company asserts that existing ad generation platforms are too complex, time-consuming and expensive for creators. Feed argues that its portal caters to a variety of budgets, requires no marketing knowledge and takes minutes to get started. The beta platform is integrated with Facebook's & Instagram's ad network and has 500 creators on board. The company will use the investment to launch the paid version of Feed in Q4 2020.
days to go:
Expired
investment:
£146,117
YurOn is a video platform that cultivates authentic interaction between prominent personalities and their fans. The portal allows people from different walks of life–drag queens, mountaineers, activists–thirty seconds to ignite a conversation, start an Ask Me Anything or co-create a skit. YurOn shuns away filters, anonymous commenting, vanity metrics or validation-driven algorithms and endeavours to bring to the public an unadulterated conversation between stars and their fans. The portal soft-launched in Q2 of 2020 and has seen over 5000 downloads, 2000 active users, and 32% of users retaining over a month. The company will use 80% of the investment to grow its tech team and cloud infrastructure, and 20% towards marketing and partnerships to accelerate growth.
days to go:
Expired
investment:
£222,110
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
